Lasa Supergenerics Ltd - 540702 - Compliance Under Regulation 23(9) Of SEBI (Listing Obligations & Disclosure Requirements) Regulations. 2015.
Pursuant to Regulation 23 [9] of the SEBI (Listing obligations and Disclosure Requirements), Regulations, 2015, please find enclosed herewith disclosure of related party transactions for the year ended 31 March 2020. Lasa Supergenerics Ltd - 540702 - Closure of Trading Window
This is to inform you that as per the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders in terms of (Prohibition of Insider Trading) Regulations, 2015, as amended, the trading window for dealing in the equity shares of the Company has been closed for designated employees and their immediate relatives w.e.f.July 01, 2020 till 48 hours after the declaration of financial results (both days inclusive) for the quarter ended June 30, 2020. Lasa Supergenerics Ltd - 540702 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Conference call Lasa Supergenerics Ltd - 540702 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor_Presentation_Q4_FY20 Lasa Supergenerics Ltd - 540702 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings conference call for analysts on Friday, 19th June 2020 @ 05:30 p.m to discuss the Company's Q4 & FY20 financial performance
Lasa Supergenerics to produce antiviral for COVID-19; share rises 10%
The share touched its 52-week high Rs 49.70 and 52-week low Rs 9.48 on 03 March, 2020 and 06 August, 2019, respectively. Lasa Supergenerics Ltd - 540702 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
COVID 19: ICT, Lasa realise success in Favipiravir drug synthesis, to commence production Lasa Supergenerics Ltd - 540702 - Disclosure Of Material Impact Of Covid-19 Pandemic Under SEBI (Listing Obligations And Disclosure Requirements)Regulations, 2015
Pursuant to advisory issued by the Securities and Exchange Board of India (SEBI) vide its circular SEBI/HO/CFD/CMDI/CIR/P/2020/84 dated May 20, 2020 and Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements)Regulations, 2015, please find enclosed herewith disclosure on material impact of COVID-19 pandemic on the Company. Lasa Supergenerics Ltd - 540702 - Announcement under Regulation 30 (LODR)-Change in Corporate Office Address
In Compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, This is to inform you that Corporate office of the company is Shifted to office no 705, Minera Estate, A wing , 02 Commercial Tower , Mulund (W), Mumbai- 400 080. Lasa Supergenerics Ltd - 540702 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to SEBI Circular CIR/CFD/CMD1/27/2019 dated 8th February, 2019, please find enclosed copy of the of Annual Secretarial Compliance Report dated June 04, 2020, issued by Shivam Sharma & Associates, Secretarial Auditors of the Company, for the financial year 2019- 2020